Clinical Trials
2
Active:0
Completed:0
Trial Phases
1 Phases
Phase 3:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 3
2 (100.0%)ASP-II: Ancrod Stroke Program: Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
Phase 3
Terminated
- Conditions
- StrokeCerebral IschemiaBrain Infarction
- Interventions
- Biological: Ancrod (Viprinex)Drug: Placebo
- First Posted Date
- 2006-03-08
- Last Posted Date
- 2010-01-12
- Lead Sponsor
- Neurobiological Technologies
- Target Recruit Count
- 311
- Registration Number
- NCT00300196
- Locations
- 🇺🇸
Enloe Medical Center, Chico, California, United States
🇺🇸UCSF-Fresno, Fresno, California, United States
🇺🇸Sherry Braheny MD - A Prof. Corporation, La Mesa, California, United States
Ancrod (Viprinex™) for the Treatment of Acute, Ischemic Stroke
Phase 3
Terminated
- Conditions
- Brain InfarctionStrokeCerebral Ischemia
- Interventions
- Drug: Placebo
- First Posted Date
- 2005-09-01
- Last Posted Date
- 2009-12-23
- Lead Sponsor
- Neurobiological Technologies
- Target Recruit Count
- 277
- Registration Number
- NCT00141011
- Locations
- 🇺🇸
Mayo Clinic Hospital / Arizona, Phoenix, Arizona, United States
🇺🇸Sparks Regional Medical Center, Fort Smith, Arkansas, United States
🇺🇸Loma Linda University School of Medicine, Loma Linda, California, United States
News
No news found